Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

31
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

857
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
857
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

664
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
664
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.0K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.0K
Angina IV: Management01:26

Angina IV: Management

21
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The complex interplay of lipoprotein(a) and cancer in the era of emerging therapeutics.

Seminars in cancer biology·2025
Same author

Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.

American journal of preventive cardiology·2025
Same author

Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric Group.

Children (Basel, Switzerland)·2025
Same author

2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2025
Same author

Treatment with proton pump inhibitors is associated with secondary bacterial infections and sepsis in patients with COVID-19: a retrospective analysis of their joint impact on in-hospital prognosis.

Annals of medicine·2024
Same author

Advancements in risk stratification and management strategies in primary cardiovascular prevention.

Atherosclerosis·2024

Related Experiment Video

Updated: Sep 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk.

Filippo Figorilli1, Massimo R Mannarino2, Vanessa Bianconi1

  • 1Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine and Surgery, University of Perugia, Ospedale S. Maria della Misericordia, Blocco L, piano-1, Piazzale Menghini 1, 06129, Perugia, Italy.

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
|June 27, 2022
PubMed
Summary

Elevated low-density lipoprotein cholesterol (LDL-C) significantly increases atherosclerotic cardiovascular disease (ASCVD) risk. This review examines evidence for treating LDL-C in low-to-moderate risk individuals to improve long-term outcomes.

Keywords:
Cardiovascular riskCholesterolCholesterol-lowering treatmentPrimary prevention

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

Related Experiment Videos

Last Updated: Sep 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Lipid Metabolism

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Reducing LDL-C levels is proven to decrease major adverse cardiovascular events (MACEs), with benefits correlating to baseline risk and LDL-C reduction.
  • Current European guidelines offer revised cardiovascular risk assessment, considering risk factor interactions and confounders like age.

Purpose of the Study:

  • To review current evidence influencing treatment decisions for LDL-C elevation in low-to-moderate cardiovascular risk individuals.
  • To explore therapeutic strategies for achieving target LDL-C goals in this patient group.

Main Methods:

  • Literature review of recent evidence on LDL-C management.
  • Analysis of European guidelines on cardiovascular prevention.
  • Evaluation of risk stratification and treatment benefit assessment.

Main Results:

  • Treatment decisions for LDL-C in low-to-moderate risk patients remain debated.
  • Even mild LDL-C elevations can negatively impact long-term cardiovascular prognosis.
  • Conservative lifestyle changes and pharmacologic interventions should be considered.

Conclusions:

  • The management of LDL-C in low-to-moderate risk individuals requires careful consideration of long-term prognosis.
  • Tailored interventions, including lifestyle modifications and pharmacotherapy, may be beneficial.
  • Further research may refine treatment thresholds and strategies for this population.